Characteristics | Baseline | Year 1 |
---|---|---|
Male sex, n (%) | 67 (92%) | – |
Age, years | 58 (49 to 65) | – |
Pacific ethnicity, n (%) | 25 (34%) | – |
Māori ethnicity, n (%) | 18 (25%) | – |
European and other ethnicities, n (%) | 30 (41%) | – |
Gout disease duration, years | 23 (16 to 28) | – |
Flare frequency (in the preceding three months) | 0 (0 to 2) | 0 (0 to 2) |
Allopurinol use, n (%) | 62 (85%) | 62 (85%) |
Allopurinol dose (n = 62), mg/day | 300 (200 to 300) | 300 (200 to 300) |
Colchicine use, n (%) | 33 (45%) | 32 (44%) |
Nonsteroidal anti-inflammatory drug use, n (%) | 46 (63%) | 44 (60%) |
Prednisone use, n (%) | 11 (15%) | 12 (16%) |
Health assessment questionnaire II score | 0.2 (0 to 0.55) | 0.15 (0 to 0.58) |
Swollen joint count | 0 (0 to 0) | 0 (0 to 0) |
Tender joint count | 0 (0 to 1) | 0 (0 to 1) |
Number of subcutaneous tophi | 3 (2 to 9) | 3.5 (2 to 8) |
Serum creatinine, μmol/L | 99 (84 to 112.5) | 96 (81 to 112) |
C-reactive protein, mg/L | 2.4 (1 to 5) | 2.1 (1 to 6) |
Serum urate, mmol/L | 0.36 (0.18 to 0.46) | 0.37 (0.32 to 0.46) |
Serum urate <0.36 mmol/L, n (%) | 34 (47%) | 29 (40%) |
Serum urate <0.36 mmol/L at both time points, n (%) | 21 (29%) |